Early access
Sign in
Taking people in NetherlandsPhase 2

Scan test for early bone changes in people with psoriasis

Tests a fluoride body scan to find early bone changes in adults with psoriasis.

Key facts

Who runs it
Stichting Amsterdam UMC
Where
Amsterdam, NetherlandsSee the site
Registry title
[18F]Fluoride PET-CT in psoriasis patients at risk for developing psoriatic arthritis
Status
Recruiting
Phase
Phase 2
People taking part
15 people, planned
Started
16 Dec 2024
Expected to end
1 May 2027
Type of study
Interventional
Record updated
16 December 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with psoriasis who have recent joint or tendon-attachment pain and may be at risk of developing psoriatic arthritis. They will have a whole-body [18F]Fluoride PET-CT scan.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Diagnosis of psoriasis, with at least 1 painful joint and/or tendon-attachment problem (arthralgia and/or enthesiopathy) in at least 1 place for 1 year or less, not caused by an injury. Also at least 1 of these: nail psoriasis, a first-degree relative with psoriatic arthritis, and/or psoriasis covering 3% or more of the body surface (BSA ≥3%).
Earlier treatment
People who had systemic therapy for psoriasis (DMARD, bDMARD) or study medication in the past 3 months cannot join.

Main reasons for not taking part

  • Another rheumatic disease (such as Axial SpA, RA, SLE, Sjögren)
  • Osteoarthritis and/or a mechanical cause of the joint or tendon pain
  • Clearly visible arthritis (and/or tenosynovitis)
  • Systemic therapy for psoriasis (DMARD, bDMARD)
  • Pregnancy or breast-feeding

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patients with a diagnosis of psoriasis and an age of 18 years or older
  • ≥1 arthralgia and/or enthesiopathy in ≥1 location(s) ≤ 1 year, not secondary to trauma
  • ≥1 of the following: Nail psoriasis, First-degree relative with PsA and/or BSA ≥3%

Who cannot take part

  • Systemic therapy for psoriasis (DMARD, bDMARD)
  • Treatment with study medication in the past 3 months
  • Other rheumatic disease (such as Axial SpA, RA, SLE, Sjögren)
  • Osteoarthritis and/or mechanical explanation of the pain in joints and/or tendons
  • Clinically evident arthritis (and/or tenosynovitis)
  • Pregnancy or breast-feeding

Where in Netherlands

  • Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people

About the trial

What the trial wants to find out

The primary objective of this proof-of-concept study is to investigate the feasibility of whole body [18F]Fluoride PET-CT scans to detect axial and peripheral new bone formation, in psoriasis patients that are at risk to develop clinically manifest psoriatic arthritis.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
[18F]Fluoride PET-CT in psoriasis patients at risk for developing psoriatic arthritis
Plain-language title
Scan test for early bone changes in people with psoriasisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
16 December 2024